NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Arbutus Biopharma Corporation (ABUS) Stock Analysis

Arbutus Biopharma Corporation (ABUS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ABUS

$5.15

+$0.03 (+0.59%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ABUS with… →

ABUS Key Statistics

As of Sep 4, 2026
Trading
Open
$5.09
Previous Close
$5.12
Day's Range
5.09–5.17
52-Week Range
3.50–5.45
Volume
5.20M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.62
Valuation
Market Cap
$1.02B
P/E Ratio
6.52
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
5.61
EPS (ttm)Profit attributable to each share over the last twelve months.
0.79
Financials (FY)
Revenue (FY)
$14.08M+128.21%
Net Income (FY)
−$33.50M
Profit marginThe share of revenue left as profit after all costs and taxes.
84.23%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
198.11M
1-Year Return
+28.43%
Dividend and dates
Earnings Date
November 16, 2026estimated
Avg Volume
2.88M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ABUS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+7.07%
2025+47.09%
2024+30.80%
2023+7.30%
2022−40.10%
2021+9.58%
2020+27.70%
2019−27.42%
2018−24.16%
2017+106.12%
2016 (partial year)−37.82%

As of September 4, 2026.

ABUS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$14.08M−$33.50M−237.9%
2024$6.17M−$69.92M−1133.0%
2023$18.14M−$72.85M−401.6%
2022$39.02M−$69.46M−178.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$14.08M—−$27.05M−$33.50M−237.9%
2024$6.17M—−$69.97M−$69.92M−1133.0%
2023$18.14M—−$78.03M−$72.85M−401.6%
2022$39.02M—−$63.22M−$69.46M−178.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ABUS Valuation vs Biotechnology Median

Median of 656 stocks
MetricABUSBiotechnology medianvs median
P/E6.5212.5748% below
P/S ratio5.6115.2663% below
Profit margin84.23%0.00%84.2 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Arbutus Biopharma Corporation (ABUS) is capitalised at $1.02B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 19 employees.

The 52-week range on file runs from $3.50 to $5.45. The most recent close on file for ABUS is $5.15, dated September 4, 2026. That is +$0.03 (+0.59%) against the previous close. The latest close sits 47.14% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $14.08M. Against the prior fiscal year total of $6.17M, that is a change of +128.21%. The same year closed with a net loss of $33.50M. Profit margin runs at 84.23%. That is 84.2 percentage points above the Biotechnology median of 0%. Earnings per share on a trailing basis come to 0.79.

Across the 4 fiscal years on file, revenue moves from $39.02M in 2022 to $14.08M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 6.52. That is 48.13% below the Biotechnology median of 12.57. The price-to-sales ratio is 5.61. On price-to-sales that is 63.22% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +28.43%. Across 10 years the annualized return works out at +3.20%. Beta against the wider market is reported at 0.62. Daily returns over the trailing 10 years annualize to a volatility of 85.36%.

Growth & Income

The record shows no dividend for ABUS.

2026 is still running; the price is +7.07% year to date. Across the complete calendar years on file, 2017 returned +106.12% and 2022 returned −40.10%. Of the 9 complete calendar years on file, 6 finished higher.

Peer Comparison

Arbutus Biopharma Corporation (ABUS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Arbutus Biopharma Corporation ABUS $1.02B 6.5
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Arbutus Biopharma Corporation trades at a P/E of 6.5.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Arbutus Biopharma Corporation

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

Visit website →